Fumonisin B2 is a selective ceramide synthase inhibitor and carcinogenic mycotoxin. It inhibits de novo sphingolipid biosynthesis by blocking amide bond formation, leading to altered sphingolipid levels, inhibition of cell proliferation, and induction of cell death. This product is utilized to investigate the pathogenesis of diseases associated with *Fusarium verticillioides* contamination.
- Selective ceramide synthase inhibitor and carcinogenic mycotoxin.
- Inhibits de novo sphingolipid biosynthesis.
- Used for investigating diseases related to *Fusarium verticillioides* contamination.
- Demonstrates inhibition of cell proliferation in vitro.
- Shows effects on body weight, food consumption, and serum markers in vivo.
- Induces cellular changes in liver and kidney in animal models.